VolitionRX (NYSEAMERICAN:VNRX) Stock Price Crosses Below Fifty Day Moving Average – Here’s What Happened

Shares of VolitionRX Limited (NYSEAMERICAN:VNRX) passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.68 and traded as low as $0.99. VolitionRX shares last traded at $1.00, with a volume of 176,127 shares trading hands.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on VNRX shares. Maxim Group restated a “buy” rating and issued a $4.00 target price on shares of VolitionRX in a report on Thursday, June 18th. HC Wainwright lowered their price objective on shares of VolitionRX from $30.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, April 2nd. Citigroup lowered shares of VolitionRX to a “hold” rating in a research note on Monday, April 20th. Benchmark reiterated a “hold” rating on shares of VolitionRX in a research report on Tuesday, June 2nd. Finally, D. Boral Capital reissued a “hold” rating on shares of VolitionRX in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, VolitionRX has an average rating of “Hold” and a consensus target price of $28.00.

VolitionRX Stock Performance

The stock has a market cap of $8.63 million, a P/E ratio of -0.24 and a beta of 1.12. The firm has a 50 day moving average of $1.68 and a two-hundred day moving average of $3.30.

VolitionRX (NYSEAMERICAN:VNRX) last announced its quarterly earnings data on Thursday, May 14th. The medical research company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.27). The firm had revenue of $0.99 million for the quarter, compared to analyst estimates of $1.52 million. On average, sell-side analysts anticipate that VolitionRX Limited will post -2.4 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Virtu Financial LLC bought a new stake in VolitionRX in the 3rd quarter valued at $28,000. Northwestern Mutual Wealth Management Co. acquired a new position in VolitionRX in the second quarter worth about $52,000. Geode Capital Management LLC lifted its stake in VolitionRX by 9.8% during the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after purchasing an additional 85,816 shares during the period. Jane Street Group LLC acquired a new position in shares of VolitionRX in the 4th quarter worth approximately $28,000. Finally, Squarepoint Ops LLC acquired a new position in shares of VolitionRX in the 4th quarter worth approximately $34,000. 8.09% of the stock is currently owned by institutional investors and hedge funds.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.